| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.2 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.2 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.063 | 0.3 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.3 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |